Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14409593 | 0.81 | CXCR4 (0.45) | POLBHTR6CXCR4TLR8CYP1A2 | |
| SCHEMBL14409589 | 0.80 | POLB (0.43) | POLBCXCR4TLR8CYP1A2ALDH1A1 | |
| SCHEMBL25171851 | 0.79 | CYP1A2 (0.59) | POLBKDM4ECXCR4TLR8CYP1A2 | |
| SCHEMBL16512785 | 0.79 | TLR8 (0.64) | POLBCXCR4TLR8 | |
| SCHEMBL6930946 | 0.78 | POLB (0.69) | TOP2APOLBCXCR4TLR8CYP1A2 | |
| Hydrochloric Acid SCHEMBL31258765 | 0.78 | CYP1A2 (0.57) | POLBKDM4ECXCR4TLR8CYP1A2 | |
| Hydrochloric Acid SCHEMBL25167011 | 0.78 | CYP1A2 (0.57) | POLBKDM4ECXCR4TLR8CYP1A2 | |
| Hydrochloric Acid SCHEMBL6934113 | 0.77 | POLB (0.67) | TOP2APOLBCXCR4TLR8CYP1A2 | |
| SCHEMBL19233647 | 0.75 | HTR3E (0.42) | KDM4E | |
| SCHEMBL14409579 | 0.72 | CXCR4 (0.38) | POLBCXCR4TLR8CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219191-A1 | 3-Pyridinium Methyl Cephem Compound | SHIONOGI & CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070219191-A1 | 3-Pyridinium Methyl Cephem Compound | SHIONOGI & CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219191-A1 | 3-Pyridinium Methyl Cephem Compound | ABL1, CRKL, MGMT | TOP2A 4056/4885POLB 3049/4885KDM4E 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.